Cargando…

State policy influence on the early diffusion of buprenorphine in community treatment programs

BACKGROUND: Buprenorphine was approved for use in the treatment of opioid dependence in 2002, but its diffusion into everyday clinical practice in community-based treatment programs has been slow. This study examines the net impact of efforts by state agencies, including provision of Medicaid covera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducharme, Lori J, Abraham, Amanda J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464589/
https://www.ncbi.nlm.nih.gov/pubmed/18570665
http://dx.doi.org/10.1186/1747-597X-3-17
_version_ 1782157425417125888
author Ducharme, Lori J
Abraham, Amanda J
author_facet Ducharme, Lori J
Abraham, Amanda J
author_sort Ducharme, Lori J
collection PubMed
description BACKGROUND: Buprenorphine was approved for use in the treatment of opioid dependence in 2002, but its diffusion into everyday clinical practice in community-based treatment programs has been slow. This study examines the net impact of efforts by state agencies, including provision of Medicaid coverage, on program-level adoption of buprenorphine as of 2006. METHODS: Interviews were conducted with key informants in 49 of the 50 state agencies with oversight responsibility for addiction treatment services. Information from these interviews was integrated with organizational data from the 2006 National Survey of Substance Abuse Treatment Services. A multivariate logistic regression model was estimated to identify the effects of state efforts to promote the use of this medication, net of a host of organizational characteristics. RESULTS: The availability of Medicaid coverage for buprenorphine was a significant predictor of its adoption by treatment organizations. CONCLUSION: Inclusion of buprenorphine on state Medicaid formularies appears to be a key element in ensuring that patients have access to this state-of-the-art treatment option. Other potential barriers to the diffusion of buprenorphine require identification, and the value of additional state-level policies to promote its use should be evaluated.
format Text
id pubmed-2464589
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24645892008-07-15 State policy influence on the early diffusion of buprenorphine in community treatment programs Ducharme, Lori J Abraham, Amanda J Subst Abuse Treat Prev Policy Research BACKGROUND: Buprenorphine was approved for use in the treatment of opioid dependence in 2002, but its diffusion into everyday clinical practice in community-based treatment programs has been slow. This study examines the net impact of efforts by state agencies, including provision of Medicaid coverage, on program-level adoption of buprenorphine as of 2006. METHODS: Interviews were conducted with key informants in 49 of the 50 state agencies with oversight responsibility for addiction treatment services. Information from these interviews was integrated with organizational data from the 2006 National Survey of Substance Abuse Treatment Services. A multivariate logistic regression model was estimated to identify the effects of state efforts to promote the use of this medication, net of a host of organizational characteristics. RESULTS: The availability of Medicaid coverage for buprenorphine was a significant predictor of its adoption by treatment organizations. CONCLUSION: Inclusion of buprenorphine on state Medicaid formularies appears to be a key element in ensuring that patients have access to this state-of-the-art treatment option. Other potential barriers to the diffusion of buprenorphine require identification, and the value of additional state-level policies to promote its use should be evaluated. BioMed Central 2008-06-20 /pmc/articles/PMC2464589/ /pubmed/18570665 http://dx.doi.org/10.1186/1747-597X-3-17 Text en Copyright © 2008 Ducharme and Abraham; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ducharme, Lori J
Abraham, Amanda J
State policy influence on the early diffusion of buprenorphine in community treatment programs
title State policy influence on the early diffusion of buprenorphine in community treatment programs
title_full State policy influence on the early diffusion of buprenorphine in community treatment programs
title_fullStr State policy influence on the early diffusion of buprenorphine in community treatment programs
title_full_unstemmed State policy influence on the early diffusion of buprenorphine in community treatment programs
title_short State policy influence on the early diffusion of buprenorphine in community treatment programs
title_sort state policy influence on the early diffusion of buprenorphine in community treatment programs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464589/
https://www.ncbi.nlm.nih.gov/pubmed/18570665
http://dx.doi.org/10.1186/1747-597X-3-17
work_keys_str_mv AT ducharmelorij statepolicyinfluenceontheearlydiffusionofbuprenorphineincommunitytreatmentprograms
AT abrahamamandaj statepolicyinfluenceontheearlydiffusionofbuprenorphineincommunitytreatmentprograms